Market prospects build for continuous glucose monitoring after bullish American Diabetes Association results
This article was originally published in Clinica
Executive Summary
Excitement is building in the US over the prospects for continuous glucose monitoring (CGM) devices, fuelled by several promising studies released at this year's annual meeting of the American Diabetes Association (ADA), in Washington, DC. "Overall, we were generally surprised by the enthusiasm for CGM," said Morgan Stanley analyst Glenn Reicin, who came away from the meeting concluding that the technology "looks to be a potentially significant market".
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.